This Special Interest Group (Endocrine R&D Networking Study Group) symposium focuses on “Endocrine Strategy for Healthy and Slow Aging,” aiming to provide an integrated view of the endocrine mechanisms underlying aging and potential therapeutic approaches. Prof. Kwang Joon Kim (Yonsei University) will present a comprehensive overview of endocrine disorders associated with aging. Dr. Ken-ichi Takayama (Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan) will discuss the mechanistic roles of androgen and estrogen signaling in preventing aging and age-related diseases. Finally, Prof. Ok Hee Jeon (Korea University) will highlight the role of circulating senescent cell–derived progeronic factors in musculoskeletal aging. This session will offer valuable insights into endocrine-driven aging processes and future intervention strategies.

This session will provide a multi-dimensional perspective on translating basic senescence mechanisms into holistic therapeutic strategies for cardiometabolic health. Dr. Hu will discuss how muscle-derived metabolites and proteins orchestrate sarcopenia, while Dr. Kim will define the early aging-associated niches in the liver using a quasi-spatial single-cell transcriptomic approach. Dr. Hsiao will present novel immunotherapeutic vaccination strategies targeting cardiometabolic diseases

The Special Interest Group for Rare Endocrine Diseases will host a session focusing on rare but clinically significant malignant tumors. Prof. Jung Soo Lim will introduce clinical approaches to adrenocortical carcinoma, and Prof. Dong-Jun Lim is expected to discuss the complexities and treatment limitations of anaplastic thyroid carcinoma. Finally, Prof. Seiji Fukumoto will explore the intersection of bone metabolism and endocrine diseases through the study of rare malignancies causing TIO. We hope this session serves as a meaningful platform to discuss the future of rare endocrine cancer management.

The landscape of thyroid cancer treatment is shifting toward risk-stratified precision medicine. In this session, we will share multicenter data on serum Tg cut-off levels for post-operative management in low-to-intermediate risk groups and discuss clinical strategies for active surveillance during pregnancy. Additionally, we will delve into the role of the tumor microenvironment in overcoming treatment resistance in advanced stages. We invite you to join us for an insightful overview of the evolving paradigms, spanning the entire spectrum from low-risk management to high-risk therapeutic interventions.